Joshua Silverman

Aromyx Corp. engages in the using of biological receptors from the human nose to create digital representations of smell sensory data for multiple application. Its products include EssenceChip, EssenceCapture, EssenceAnalytics, and EssenceCloud. The company was founded by Chris Hanson and is headquartered in Palo Alto, CA.

Windfall Bio is a technology company based in the US that specializes in developing nature-based solutions. The American company has created a methane-to-value solution that utilizes methane-eating microbes to convert harmful emissions into organic soil nutrients. This technology can be applied in various industries such as oil and gas, landfills, and waste management, as well as in agricultural settings. Windfall Bio's solution aims to reduce the carbon footprint of the food system and increase profits for farmers without increasing costs for consumers.

Amunix, Inc. develops protein pharmaceuticals. It offers XTEN which is hydrophilic, unstructured, biodegradable polypeptides that impart a number of favorable properties upon the molecules to which they are attached. The company was founded by Volker Schellenberger and Willem Stemmer in 2006 and is headquartered in Mountain View, CA.

Calysta, Inc. provides sustainable industrial products for food and energy security. The firm develops new Biological Gas-to-Liquids and Biological Gas-to-Chemicals technologies using methane, the primary component of natural gas. It’s technology allows conversion of a plentiful energy resource into high value chemicals and transportation fuels. The company was founded in 2012 by Joshua Silverman and Alan Shaw and is headquartered in Menlo Park, CA.

Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA.